(¿Â¶óÀÎ) ´ëÇѵÎÅëÇÐȸ2021 Ãß°èÇмú´ëȸ : 2021-12-19±³À°ÀÏÀÚ : 2021-12-19
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°(ÃßÈÄ »çÀüµî·ÏÀÚ ÇÑÇØ °³º°ÀûÀ¸·Î Á¢¼Ó »çÀÌÆ® ¸µÅ© ¾È³» ¿¹Á¤)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) ´ëÇѵÎÅëÇÐȸ2021 Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѵÎÅëÇÐȸ
´ã´çÀÚ : ´ëÇѵÎÅëÇÐȸ ¿î¿µ»ç¹«±¹
¿¬¶ôó : 02-476-6718
À̸ÞÀÏ :
headache@ls-comm.co.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, ½Å°æ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, °¡Á¤ÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í Æò»ýȸ¿ø¹×¿¬È¸ºñ³³ºÎÁ¤È¸¿ø 30,000¿ø, ¿¬È¸ºñ¹Ì³³Á¤È¸¿ø 30,000¿ø,ºñȸ¿ø 60,000¿ø, Àü°øÀÇ¹× ±âŸȸ¿ø&±ºÀÇ°ü¹× °øº¸ÀÇ µî·Ïºñ¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 09:10~09:30 µÎÅë ȯÀÚ º´·ÂûÃë & µÎÅëÀϱâ Á¶¼öÇö(À»ÁöÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 09:30~09:50 µÎÅë»óÅÂÆò°¡ ¼ÕÁ¾Èñ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 09:50~10:10 ¼Ò¾Æû¼Ò³â µÎÅëȯÀÚ °¨º°ÇÏ°í Áø´ÜÇϱ⠱ÇÇýÀº(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 10:10~10:30 µÎÅëÀÇ ºñ°æ±¸Ä¡·á ¹ÚÈ«±Õ(ÀÎÁ¦ÀÇ´ë)
ÈÞ½Ä 12-19 - 10:30~10:40 ÈÞ½Ä -(-)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 10:40~10:55 °©Àڱ⠹߻ýÇÑ µÎÅëÀ¸·Î ³»¿øÇÑ È¯ÀÚ Á¤ÇÊ¿í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 10:55~11:10 ¼ö°³¿ùÀüºÎÅÍ Áö¼ÓµÇ´Â µÎÅëÀ¸·Î ³»¿øÇÑ È¯ÀÚ ¼ÛÅÂÁø(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 11:10~11:25 º¹¿ë¾à¹°ÀÌ 10°¡Áö ÀÌ»óÀÎ µÎÅë ȯÀÚ ±è°æ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 11:25~11:45 °í³úô¼ö¾×¾Ð°ú Àú³úô¼ö¾Ð¿¡ ÀÇÇÑ µÎÅëÀÇ ¿µ»óÁø´Ü ±èÀÀ¿±(¼º±Õ°üÀÇ´ë)
Åä·Ð 12-19 - 11:45~12:00 Q&A -(-)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 12:00~12:20 (Luncheon Symposium)Practical application of anti-CGRP therapy in real world ¹®Èñ¼ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 12:20~12:50 (Luncheon Symposium)New options for migraine treatment: recent experiences on monoclonal antibodies, ditans, and gepants Andrew Charles(David Geffen School of Medicine at UCLA)
Åä·Ð 12-19 - 12:50~13:00 Q&A -(-)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 13:00~13:30 ¼Ò¾Æ µÎÅëȯÀÚ¸¦ Áø·áÇϸé¼.... ÀÌ°ÇÈñ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 13:30~14:00 Back to the Future: Reflections on My Á¤Áø»ó(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 12-19 - 14:00~14:30 ÈÞ½Ä -(-)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 14:30~15:00 Topic 1: ¿©·¯ »óȲ¿¡¼ÀÇ ¾à¹°Ä¡·á (¼ö¼úÀüÈÄ, ÀÓ½Å,¼öÀ¯, Æó°æ, ½ÃÇèÀüÈÄ, Çù½ÉÁõ) ±èº´¼ö ¸ðÈñÁ¤(ºÐ´çÁ¦»ýº´¿ø ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 15:00~15:30 Topic 2: µ¿¹ÝÁõ»ó ¹× µ¿¹ÝÀÌȯ Ä¡·áÇϱâ (À§ÀåÀå¾Ö, ¾îÁö·³Áõ, ¼¶À¯±ÙÅë, ¸ñÅëÁõ) ¹ÚÁ¤¿í ±è¼ºÈñ(°¡Å縯ÀÇ´ë ÀÌÈÀÇ´ë)
ÈÞ½Ä 12-19 15:30~15:40 ÈÞ½Ä ()
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 15:40~16:20 µÎÅëÀÇ ½Å°æÂ÷´Ü¼ú Ä¡·á(°ÀÇ/½Ç½À) ¹è´ë¿õ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12-19 ¹éÁ¦1Ȧ 16:20~17:00 ¸¸¼ºÆíµÎÅëÀÇ º¸Æ«¸®´½µ¶¼Ò Ä¡·á(°ÀÇ/½Ç½À) ±è´ÙÀº(½ÅÃÌ¿¬¼¼º´¿ø)